The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Transforming growth factor beta: the good, the bad, and the ugly.
Open accessAbstract
A is often the case with peptide growth factors and cytokines, the original activity discovered and identified as TGF-3 merely represented the tip of the iceberg. Not only does it regulate growth, as evident by its name, but TGF-B mediates far-ranging biologic processes including inflammation and host defense, in addition to development, tissue repair, and tumorigenesis. Released locally from platelet stores early in an inflammatory response, TGF-3 is then generated by inflammatory cells themselves as part of the cytokine network. Initially, in its defensive role, TGF-~ mediates the egress of undifferentiated leukocytes and, subsequently, it facilitates resolution of inflammation and promotes tissue repair (1, 2). But this carefully choreographed series of events, which represents the "good" side of TGF-3, is dependent upon a critical balance of the growth factor. It is becoming increasingly evident that too much of a good thing can be bad; excess TGF-B within a lesion has been associated with unresolved inflammation and fibrotic events (1-3). Now, it appears, based on the study by Lowrance et al. (4) in the MRL/Ipr autoimmune murine model, that TGF-3 has an even uglier side, in that its accumulation in the circulation may predispose the host to serious and recurrent infections. Moreover, in humans, genetic and acquired diseases such as systemic lupus erythematosis (SLE) may mirror the MRL/lpr mouse. Under the best of circumstances, TGF-3 provides a link between each of the processes by which cells and/or tissues respond to infection or injury and initiate repair. By increasing adhesion molecules, generating a potent chemotactic gradient, and inducing itself and an array of other factors as part of the cytokine network (5-7), TGF-~ orchestrates leukocyte recruitment and activation. TGF-13 then downregulates these processes by inhibiting the functions of inflammatory cells once they are activated (2, 8) and facilitates healing by promoting fibroblast recruitment and matrix synthesis (3). As recently reviewed (2), this apparent contradictory influence of TGF-3 on cells of the immune system, both stimulatory and inhibitory, is accounted for, in part by the differential effects of TGF-3 on resting and activated cells. As a general, but by no means exclusive rule, resting, immature ceils are stimulated by TGF-3, whereas activated representatives of the same cell populations may be inhibited by TGF-3. Thus, TGF-3 serves as a conversion factor, converting an active inflammatory site into one dominated by resolution and repair. Upsetting the delicate balance of TGF-3 that dictates these events may have pathologic consequences. Indeed, persistent stimulation of immune/inflammatory events by internal or external challenges can overload the balance with chronic secretion of TGF-B. Not only might this local excess lead to unresolved inflammation (9), but also, TGF-~/may reach the circulation. When elevated systemic levels of TGF-13 occur, either endogenously during disease states (4, 10), or after exogenous administration (11-14), a plethora of additional cellular targets and consequently, diverse signaling pathways with different outcomes, may become operative. Although the source(s) of the endogenous levels of blood TGF-/3 is uncertain in the autoimmune MRL/lpr mice, the spleen may contribute to the circulating pool in this and perhaps other models characterized by immune malfunction (4, 15). Why TGF-/~ accumulates is unknown, but TGF-/~ autoinduces its own synthesis (7). In addition, dysregulation of its activity because of persistence of the enzymatic machinery essential for its activation or insu~cient levels of inhibitors may be contributory. Nonetheless, whereas the tightly controlled, localized production of TGF-B occurs as a necessary component of an active inflammatory process, the aftermath of excess TGF-B, now found in the circulation, is to inhibit the same immune and inflammatory pathways. It is not inconceivable that this built-in negative feedback loop, occurring in TGF-B excess, evolved for the protection of the host during bouts of rampant inflammation. The dichotomy between local and systemically disseminated TGF-B was first documented in an experimental arthritis model in which local secretion or administration of TGF-13 was found to drive the inflammatory response, whereas systemic inoculation inhibited the same response (9, 13, 16) (Fig. 1). By what mechanism(s) does circulating TGF-3 promote immune suppression and can these pathways be used to clinical advantage? Recent evidence suggests that systemic TGF-13 targets endothelial ceUs, where it inhibits E-selectin expression to block adhesion and targeting of leukocytes to the site of inflammation (17) (Fig. 2). Moreover, since leukocytes are normally sensitive to a concentration gradient of chemotactic signals emanating from the site of inflammation (5, 9), the presence of elevated TGF-3 in the blood would destroy such an outward gradient (Fig. 2). Evidently, the effects of secreted or exogenous TGF-3 extend far beyond the control of cell growth and differentiation to include a myriad of other regulatory activities converging on phagocytic cells and activated lymphoid cells of all lineages (reviewed in 1, 2). While it
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide as a secretory product of mammalian cells
Nathan, C. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.12.1381691 · Cited by 4,350
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985
Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C., Roberts, A. B., Sporn, M. B., Ward, J. M., & Karlsson, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.770 · Cited by 1,967
Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.
Wahl, S. M., Hunt, D. A., Wakefield, L. M., McCartney-Francis, N., Wahl, L. M., Roberts, A. B., & Sporn, M. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5788 · Cited by 1,272
Self-citationTransforming growth factor-beta in disease: the dark side of tissue repair.
Border, W. A., & Ruoslahti, E. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115821 · Cited by 1,105
Accelerated Healing of Incisional Wounds in Rats Induced by Transforming Growth Factor-β
Mustoe, T. A., Pierce, G. F., Thomason, A., Gramates, P., Sporn, M. B., & Deuel, T. F. (1987) · Science · doi:10.1126/science.2442813 · Cited by 941
Deactivation of macrophages by transforming growth factor-β
Tsunawaki, S., Sporn, M., Ding, A., & Nathan, C. (1988) · Nature · doi:10.1038/334260a0 · Cited by 861
Inhibition of Viral Replication by Interferon-γ-Induced Nitric Oxide Synthase
Karupiah, G., Xie, Q.-W., Buller, R. M. L., Nathan, C., Duarte, C., & MacMicking, J. D. (1993) · Science · doi:10.1126/science.7690156 · Cited by 816
Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta.
Vodovotz, Y., Bogdan, C., Paik, J., Xie, Q. W., & Nathan, C. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.605 · Cited by 655
Suppression of arthritis by an inhibitor of nitric oxide synthase.
McCartney-Francis, N., Allen, J. B., Mizel, D. E., Albina, J. E., Xie, Q. W., Nathan, C. F., & Wahl, S. M. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.749 · Cited by 645
Self-citation
Cited by
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605
Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1112 · Cited by 3,166
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
TRANSFORMING GROWTH FACTOR-β REGULATION OF IMMUNE RESPONSES
Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A.-K. L., & Flavell, R. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090737 · Cited by 2,206
REGULATION OF IMMUNE RESPONSES BY TGF-β
Letterio, J. J., & Roberts, A. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.137 · Cited by 1,890
IL-17 family cytokines and the expanding diversity of effector T cell lineages
Weaver, C. T., Hatton, R. D., Mangan, P. R., & Harrington, L. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141557 · Cited by 1,842
Th17: An Effector CD4 T Cell Lineage with Regulatory T Cell Ties
Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M., & Murphy, K. M. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.002 · Cited by 1,422
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily
Bootcov, M. R., Bauskin, A. R., Valenzuela, S. M., Moore, A. G., Bansal, M., He, X. Y., Zhang, H. P., Donnellan, M., Mahler, S., Pryor, K., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11514 · Cited by 1,177
Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo
Crawford, S. E., Stellmach, V., Murphy-Ullrich, J. E., Ribeiro, S. M. F., Lawler, J., Hynes, R. O., Boivin, G. P., & Bouck, N. (1998) · Cell · doi:10.1016/s0092-8674(00)81460-9 · Cited by 1,174
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Cell · doi:10.1016/s0092-8674(00)81109-5 · Cited by 970
Homeostasis and Self-Tolerance in the Immune System: Turning Lymphocytes off
Parijs, L. V., & Abbas, A. K. (1998) · Science · doi:10.1126/science.280.5361.243 · Cited by 965
Smythies, L. E., Sellers, M. T., Clements, R. H., Mosteller‐Barnum, M., Meng, G., Benjamin, W. H., Orenstein, J. M., & Smith, P. D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci19229 · Cited by 928
Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease
Monteleone, G., Kumberova, A., Croft, N. M., McKenzie, C., Steer, H. W., & MacDonald, T. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12821 · Cited by 600
Neutrophil-Derived Proteins: Selling Cytokines by the Pound
Cassatella, M. A. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60791-9 · Cited by 560
TGF-β Induces Foxp3 + T-Regulatory Cells from CD4 + CD25 − Precursors
Fu, S., Zhang, N., Yopp, A. C., Chen, D., Mao, M., Chen, D., Zhang, H., Ding, Y., & Bromberg, J. S. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00566.x · Cited by 541
Review: Role of Blood Platelets in Infection and Inflammation
Klinger, M. H. F., & Jelkmann, W. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900260286623 · Cited by 505
Regulation of Cytochromes P450 During Inflammation and Infection
Morgan, E. T. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709002246 · Cited by 488
Zhang, Z.-X., Yang, L., Young, K. J., DuTemple, B., & Zhang, L. (2000) · Nature Medicine · doi:10.1038/77513 · Cited by 459
Growth factors for bone growth and repair: IGF, TGFβ and BMP
Linkhart, T. A., Mohan, S., & Baylink, D. J. (1996) · Bone · doi:10.1016/s8756-3282(96)00138-x · Cited by 440
Koeneman, K. S., Yeung, F., & Chung, L. W. K. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990601)39:4<246::aid-pros5>3.0.co;2-u · Cited by 440
The duality of the inflammatory response to traumatic brain injury
McIntosh, T. K., Lenzlinger, P. M., Morganti-Kossmann, M.-C., & Laurer, H. L. (2001) · Molecular Neurobiology · doi:10.1385/mn:24:1-3:169 · Cited by 428
Maekawa, T., Krauss, J. L., Abe, T., Jotwani, R., Triantafilou, M., Triantafilou, K., Hashim, A., Hoch, S., Curtis, M. A., Nussbaum, G., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.05.012 · Cited by 426
A mechanism of suppression of TGF–β/SMAD signaling by NF-κB/RelA
Bitzer, M., von Gersdorff, G., Liang, D., Dominguez-Rosales, A., Beg, A. A., Rojkind, M., & Böttinger, E. P. (2000) · Genes & Development · doi:10.1101/gad.14.2.187 · Cited by 421
Ashcroft, G. S., Lei, K., Jin, W., Longenecker, G., Kulkarni, A. B., Greenwell-Wild, T., Hale-Donze, H., McGrady, G., Song, X.-Y., & Wahl, S. M. (2000) · Nature Medicine · doi:10.1038/80489 · Cited by 417
Self-citationRole of Transforming Growth Factor–β in Airway Remodeling in Asthma
Halwani, R., Al-Muhsen, S., Al-Jahdali, H., & Hamid, Q. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0027tr · Cited by 404
Veldhoen, M., Hocking, R. J., Flavell, R. A., & Stockinger, B. (2006) · Nature Immunology · doi:10.1038/ni1391 · Cited by 403
The cell biology of thrombospondin-1
Chen, H., Herndon, M. E., & Lawler, J. (2000) · Matrix Biology · doi:10.1016/s0945-053x(00)00107-4 · Cited by 393
Periapical Inflammatory Responses and Their Modulation
Stashenko, P., Teles, R., & D'Souza, R. (1998) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/10454411980090040701 · Cited by 392
Fadok, V. A., Bratton, D. L., Guthrie, L., & Henson, P. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6847 · Cited by 366
Chen, W., Jin, W., & Wahl, S. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.10.1849 · Cited by 352
Self-citationEndoglin modulates cellular responses to TGF-beta 1.
Lastres, P., Letamendía, A., Zhang, H., Rius, C., Almendro, N., Raab, U., López, L. A., Langa, C., Fabra, A., Letarte, M., et al. (1996) · The Journal of cell biology · doi:10.1083/jcb.133.5.1109 · Cited by 304
Jobling, M. F., Mott, J. D., Finnegan, M. T., Jurukovski, V., Erickson, A. C., Walian, P. J., Taylor, S. E., Ledbetter, S., Lawrence, C. M., Rifkin, D. B., et al. (2006) · Radiation Research · doi:10.1667/rr0695.1 · Cited by 300
Bernasconi, P., Torchiana, E., Confalonieri, P., Brugnoni, R., Barresi, R., Mora, M., Cornelio, F., Morandi, L., & Mantegazza, R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118101 · Cited by 297
Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies
Lundberg, I., Ulfgren, A., Nyberg, P., Andersson, U., & Klareskog, L. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400514 · Cited by 271
Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype
Lutgens, E., Cleutjens, K. B. J. M., Heeneman, S., Koteliansky, V. E., Burkly, L. C., & Daemen, M. J. A. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7464 · Cited by 271
Floc'h, A. L., Jalil, A., Vergnon, I., Chansac, B. L. M., Lazar, V., Bismuth, G., Chouaib, S., & Mami-Chouaib, F. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061524 · Cited by 269
Regulatory T cells and inflammatory bowel disease
Groux, H., & Powrie, F. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01510-8 · Cited by 258
Apelt, J., & Schliebs, R. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03176-0 · Cited by 257
Delayed Wound Healing in Immunodeficient TGF-β1 Knockout Mice
Crowe, M. J., Doetschman, T., & Greenhalgh, D. G. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00010.x · Cited by 194
Gomez-Escobar, N., Gregory, W. F., & Maizels, R. M. (2000) · Infection and Immunity · doi:10.1128/iai.68.11.6402-6410.2000 · Cited by 162
Ito, M., Blumberg, B. M., Mock, D. J., Goodman, A. D., Moser, A. B., Moser, H. W., Smith, K. D., & Powers, J. M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.10.1004 · Cited by 125
Cytokine expression and microglial activation in progressive supranuclear palsy
Fernández-Botrán, R., Ahmed, Z., Crespo, F. A., Gatenbee, C., Gonzalez, J., Dickson, D. W., & Litvan, I. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.06.007 · Cited by 93
SMAD regulatory networks construct a balanced immune system
Malhotra, N., & Kang, J. (2013) · Immunology · doi:10.1111/imm.12076 · Cited by 92
Merson, T. D., Binder, M. D., & Kilpatrick, T. J. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8112-z · Cited by 84
Neutrophilic Lung Inflammation Suppressed by Picroside II Is Associated with TGF-β Signaling
Noh, S., Ahn, K.-S., Oh, S.-R., Kim, K. H., & Joo, M. (2015) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2015/897272 · Cited by 13
Metadata
- Authors
- Wahl, S. M.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1994-11-01
- Volume
- 180
- Issue
- 5
- Pages
- 1587-1590
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2085419002
- Cited by
- 486
- References
- 31
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.